Brief: Ampio Begins Phase 1 Clinical Trial Of Inhaled Ampion For Covid-19 Patients With Respiratory Distress
28/10/2020 11:32
Oct 28 (Reuters) - Ampio Pharmaceuticals Inc AMPE.A :
* AMPIO BEGINS PHASE 1 CLINICAL TRIAL OF INHALED AMPION FOR
COVID-19 PATIENTS WITH RESPIRATORY DISTRESS
Source text for Eikon: ID:nPn9r1Hkra
Further company coverage: AMPE.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ampio Pharmaceuticals
See all newsBrief: Ampio Announces Voluntary Delisting And SEC Deregistration
Brief: Ampio Provides Update On Results From Pre-IND Enabling Studies
Brief: Ampio Selects Ascendia Pharmaceuticals, Inc. To Provide CDMO Services To Support Clinical Development Of OA-201
Brief: Ampio Pharmaceuticals Announces Reverse Stock Split
Brief: Ampio Pharmaceuticals Inc - Holds Approximately $1.25 Million In A Deposit Account At Silicon Valley Bank